Oligometastatic breast cancer: Dissecting the clinical and biological uniqueness of this emerging entity. Can we pursue curability?
Federica Miglietta(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Luca Visani(Azienda Ospedaliero-Universitaria Careggi), Michele Bottosso(University of Padua), Maria Vittoria Dieci(Istituto Oncologico Veneto), Gaia Griguolo(University of North Carolina at Chapel Hill), Sabrina Marini(University of Padua), Icro Meattini(Azienda Ospedaliero-Universitaria Careggi), Grazia Maria Vernaci(University of Padua)
Cited by 22
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
|Journal of Clinical Oncology|2007|290